Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (Annals of Hematology, (2021), 100, 5, (1181-1194), 10.1007/s00277-021-04465-4)

Michael Heuser, B. Douglas Smith, Walter Fiedler, Mikkael A. Sekeres, Pau Montesinos, Brian Leber, Akil Merchant, Cristina Papayannidis, José A. Pérez-Simón, Caroline J. Hoang, Thomas O’Brien, Weidong Wendy Ma, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Jorge E. Cortes

Research output: Contribution to journalComment/debatepeer-review

Abstract

A correction to this paper has been published: https://doi.org/10.1007/s00277-021-04545-5.

Original languageEnglish (US)
Pages (from-to)1917-1918
Number of pages2
JournalAnnals of hematology
Volume100
Issue number7
DOIs
StatePublished - Jul 2021

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial (Annals of Hematology, (2021), 100, 5, (1181-1194), 10.1007/s00277-021-04465-4)'. Together they form a unique fingerprint.

Cite this